Vici Health Sciences has announced a major expansion of its Contract Development and Manufacturing Organization (CDMO) services, adding Phase III clinical batch manufacturing and commercial product manufacturing capabilities to its portfolio. The expansion, centered at the company's Maryland facilities, marks a significant milestone in Vici's evolution as a full-service pharmaceutical development partner.
The enhanced service offering introduces comprehensive manufacturing capabilities for solid and liquid oral dosage forms, including tablets, capsules, and liquid formulations. Additionally, the company has incorporated unit dose cup manufacturing to address growing market demands for precise, pre-measured dosage packaging solutions.
"We are excited to announce these expanded capabilities, which significantly enhance our ability to span all aspects of drug development," said Anish Dhanarajan, PhD, CEO of Vici Health Sciences. He indicated that further expansions are in development, suggesting a continued growth trajectory for the company.
Advanced Manufacturing Infrastructure
The expanded operations feature state-of-the-art facilities equipped to handle various pharmaceutical manufacturing needs. A notable addition is the DEA-licensed capabilities, enabling the company to work with controlled substances for both clinical and commercial applications. This enhancement positions Vici to serve a broader range of pharmaceutical development projects requiring specialized handling and compliance measures.
Integrated Development Services
The new manufacturing capabilities complement Vici's existing expertise in:
- Formulation development
- Analytical method development
- Manufacturing process optimization
- Regulatory compliance
- CRO management
This integration creates a seamless development pathway from early-stage research through commercialization, offering pharmaceutical and biotech clients a more streamlined development process under one roof.
Quality and Compliance Focus
Operating from its Maryland facilities, Vici Health Sciences maintains rigorous quality standards across all service areas. The company's commitment to quality and efficiency remains central to its expansion strategy, ensuring consistent delivery of high-quality services to clients worldwide.
The expansion represents a strategic move to meet the evolving needs of the pharmaceutical industry, particularly for companies seeking comprehensive development and manufacturing support from a single, experienced partner.
